Q-omics provides the consensus-scored PSMB3P2 profile across patient tissues and cancer cell-line models. PSMB3P2 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, PSMB3P2 is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, PSMB3P2 RNA expression shows 3,888 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight PAAD, COAD, and STAD as cancer lineages where PSMB3P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PSMB3P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PSMB3P2 survival associations across molecular data types. PSMB3P2 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PSMB3P2 RNA expression–survival associations across cancer types. High PSMB3P2 expression shows unfavorable associations in PAAD, HNSC, LUAD, KICH and SKCM, but favorable associations in BLCA. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify PAAD as the clearest survival context for PSMB3P2 RNA expression.
This table summarizes PSMB3P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for PSMB3P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PSMB3P2 shows lower tumor expression in KIRC and higher tumor expression in COAD, ESCA and LIHC. The COAD box plot shows higher PSMB3P2 RNA expression in tumor versus normal tissue (log2 FC = +0.091, t-test p = .011).
This table shows molecular features associated with PSMB3P2 in patient tissues and cancer cell lines. In patient samples, PSMB3P2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
